|Bid||0.1300 x 0|
|Ask||0.1400 x 0|
|Day's Range||0.1250 - 0.1300|
|52 Week Range||0.1050 - 0.1950|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The big shareholder groups in CannPal Animal Therapeutics Limited (ASX:CP1) have power over the company. Institutions...
CannPal Animal Therapeutics Limited (ASX:CP1) is a company with exceptional fundamental characteristics. Upon building...
12 veterinary clinics throughout Australia are participating in the client owned animal study, with over 60 dogs expected to be enrolled in the trial. NEW SOUTH WALES, Australia, July 31, 2019 /PRNewswire/ -- Animal health company CannPal Animal Therapeutics Limited (CP1.AX) ("CannPal" or "the Company") is pleased to announce the commencement of a Phase 2A pilot dose determination study for the Company's lead drug candidate, CPAT-01, in development for pain and inflammation control in dogs.
While not a mind-blowing move, it is good to see that the CannPal Animal Therapeutics Limited (ASX:CP1) share price...
CannPal Animal Therapeutics Limited's (ASX:CP1): CannPal Animal Therapeutics Limited, a pet pharmaceutical company, engages in the research and development of animal health products in Australia. The AU$11m ma...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! CannPal Animal Therapeutics Limited (ASX:CP1) is a Read More...
If you want to know who really controls CannPal Animal Therapeutics Limited (ASX:CP1), then you’ll have to look at the makeup of its share registry. Generally speaking, as a company Read More...